S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NASDAQ:ADMP

Adamis Pharmaceuticals - ADMP Stock Forecast, Price & News

$0.33
-0.01 (-2.96%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.32
$0.34
50-Day Range
$0.33
$0.54
52-Week Range
$0.31
$1.48
Volume
697,581 shs
Average Volume
1.08 million shs
Market Capitalization
$49.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ADMP stock logo

About Adamis Pharmaceuticals (NASDAQ:ADMP) Stock

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Adamis Pharmaceuticals in a research report on Sunday, August 14th. They set a "hold" rating on the stock.

Adamis Pharmaceuticals Price Performance

Shares of ADMP traded down $0.01 during trading hours on Friday, hitting $0.33. The company had a trading volume of 697,581 shares, compared to its average volume of 1,083,751. The business has a fifty day moving average of $0.42 and a 200-day moving average of $0.49. Adamis Pharmaceuticals has a 12 month low of $0.31 and a 12 month high of $1.48.

Adamis Pharmaceuticals (NASDAQ:ADMP - Get Rating) last issued its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $1.02 million. Equities analysts forecast that Adamis Pharmaceuticals will post -0.15 EPS for the current year.

Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMP Stock News Headlines

Adamis: Q2 Earnings Snapshot
Adamis Pharmaceuticals Corp - Stock Quote ADMP
What Makes Adamis (ADMP) a New Buy Stock
Adamis Appoints Vickie Reed to Board of Directors
Adamis Pharmaceuticals reports Q1 results
Adamis Pharmaceuticals's Earnings Outlook
See More Headlines
Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMP Company Calendar

Last Earnings
8/10/2022
Today
8/19/2022
Next Earnings (Estimated)
11/28/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADMP
Fax
N/A
Employees
116
Year Founded
N/A

Profitability

Net Income
$-45,830,000.00
Pretax Margin
-4,288.86%

Debt

Sales & Book Value

Annual Sales
$2.21 million
Book Value
$0.05 per share

Miscellaneous

Free Float
148,033,000
Market Cap
$49.12 million
Optionable
Optionable
Beta
0.99

Key Executives

  • Mr. David J. Marguglio (Age 52)
    Co-Founder, CEO, Pres & Director
    Comp: $490.68k
  • Dr. Ronald B. Moss M.D. (Age 61)
    Chief Medical Officer
    Comp: $693.2k
  • Mr. David C. Benedicto (Age 61)
    Chief Financial Officer
  • Ms. Karen K. Daniels (Age 69)
    VP of Operations
  • Mr. Mark Flather
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Jennifer C. Suski
    Sr. Director of Marketing
  • Mr. Eddie Wabern Glover (Age 72)
    Chief Exec. Officer of US Compounding Inc
  • Mr. Robert B. Rothermel (Age 78)
    Consultant













ADMP Stock - Frequently Asked Questions

Should I buy or sell Adamis Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADMP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMP, but not buy additional shares or sell existing shares.
View ADMP analyst ratings
or view top-rated stocks.

How have ADMP shares performed in 2022?

Adamis Pharmaceuticals' stock was trading at $0.6050 at the start of the year. Since then, ADMP stock has decreased by 45.9% and is now trading at $0.3275.
View the best growth stocks for 2022 here
.

When is Adamis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our ADMP earnings forecast
.

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) released its quarterly earnings data on Wednesday, August, 10th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.02. The specialty pharmaceutical company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $1.02 million.

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

Who are Adamis Pharmaceuticals' major shareholders?

Adamis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include David C Benedicto, David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins and Ronald B Moss.
View institutional ownership trends
.

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $0.33.

How much money does Adamis Pharmaceuticals make?

Adamis Pharmaceuticals (NASDAQ:ADMP) has a market capitalization of $49.12 million and generates $2.21 million in revenue each year.

How many employees does Adamis Pharmaceuticals have?

The company employs 116 workers across the globe.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.adamispharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (858) 997-2400 or via email at mflather@adamispharma.com.

This page (NASDAQ:ADMP) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.